Smither John W
SEC-identified person · CIK 1559583 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Genelux Corp GNLX | Director | filed 2023 - 2026 |
| MBX Biosciences, Inc. MBX | Chief Financial Officer | filed 2026 - 2026 |
| Newamsterdam Pharma Co N.V. NAMS | Director | filed 2023 - 2026 |
| Arcutis Biotherapeutics, Inc. ARQT | Director · Chief Financial Officer | filed 2020 - 2024 |
| Applied Molecular Transport Inc. AMTI | Director | filed 2022 - 2023 |
| Effector Therapeutics, Inc. LWAC | Director | filed 2021 - 2023 |
| Principia Biopharma Inc. PRNB | Director | filed 2019 - 2019 |
| Sienna Biopharmaceuticals, Inc. SNNA | Chief Financial Officer | filed 2018 - 2019 |
| Achaogen, Inc. AKAO | Director | filed 2014 - 2018 |
| Kythera Biopharmaceuticals INC KYTH | Chief Financial Officer | filed 2012 - 2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.